Citations

Clear

1055 citation(s) found for "Small, J C".

Diffusion MRI based biomarkers reveal a Prolonged Pre-Lesional Phase of Cerebral Small Vessel Disease
Vemuri, Prashanthi, Hu, Mingzhao, Kamykowski, Michael G. , Reid, Robert I. , Therneau, Terry M, Raghavan, Sheelakumari, Cogswell, Petrice M., Griswold, Michael, Windham, B. Gwen, Jack, Clifford R., Petersen, Ronald C., Graff-Radford, Jonathan, Raghavan, Sheelakumari , Reid, Robert I , Kamykowski, Michael G , Raghavan, Sheelakumari , Vemuri, Prashanthi , Hu, Mingzhao, Lundt, Emily S. , Therneau, Terry M. , Cogswell, Petrice M. , Windham, B. Gwen , Jack, Clifford R. , Petersen, Ronald C. , Graff‐Radford, Jonathan

Mayo Clinic

No container title available | March 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.03.709452 Get It

Abstract Background White matter hyperintensities (WMH) are widely used to assess cerebral small vessel disease (SVD) but reflect late-stage injury. Diffusion MRI based biomarkers have been proposed to capture earlier SVD-related microstructural damage but their temporal progression relative to WMH and the risk factors associated with this progression have not been explored. Methods We analyzed longitudinal neuroimaging data from 2,047 participants from a population-based cohort study (aged 49-101 years, 47% female). Using multi-output nonlinear mixed-effects models, we characterized the temporal progression of WMH and four diffusion MRI based biomarkers: fractional anisotropy of the genu of the corpus callosum (Genu-FA), peak width of skeletonized mean diffusivity (PSMD), free water (FW), and Arteriolosclerosis-score (ARTS). Models incorporated participant-specific time shifts, correlations between biomarkers, and effects of risk factors (sex, education, APOE ε4 status, and cardiometabolic conditions). Results ARTS, Genu-FA, FW, and PSMD became abnormal in 50% of the study population 16, 12, 10, and 7 years before WMH, respectively. Global markers (ARTS, FW, PSMD, WMH) were correlated, indicating shared substrates of widespread white matter injury. Genu-FA, a vascular risk microstructural injury biomarker, was weakly coupled with WMH and had an earlier but more linear worsening across adulthood. Cardiometabolic conditions predicted earlier worsening of all biomarkers. Females showed earlier WMH, Genu-FA, and ARTS abnormalities whereas males exhibited earlier PSMD and FW abnormalities. Conclusions Diffusion MRI based biomarkers capture microstructural injury at least a decade before appearance of WMH, revealing a prolonged phase of early SVD and highlighting their potential for SVD prevention.
Executive Summary of the American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma
Adenocarcinoma, Expert Panel Adjuvant Therapy for Treatment of Locoregional Gastric, Tchelebi, Leila T. , Jin, Zhaohui, Attallah, Joseph, Abood, G., Akselrod, Dmitriy, Codipilly, D. Chamil, Dozois, Eric J. , Hallemeier, Christopher L., Krishan, Jethwa, Kennedy, Timothy, Lee, Percy P., Ling, Diane, Newman, Neil B. , Sharma, Navesh K, Small, William, Russo, Suzanne , Tchelebi, Leila , Jin, Zhaohui , Abood, Gerard, Akselrod, Dmitriy , Anker, Christopher J. , Codipilly, Don C. , Hallemeier, Christopher Leigh , Lee, Percy , Miller, Eric D. , Sharma, Navesh, Small, William , Russo, Suzanne

Mayo Clinic

American Journal of Clinical Oncology | February 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001309 | PMID 41712927 Get It

Objectives: To summarize recent high-quality trials and provide an update to the original 2022 American College of Radiology Appropriate Use Criteria for Treatment of Locoregional Gastric Adenocarcinoma. This multi-specialty-led committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and surgical oncology. Methods: Using the population, intervention, comparator, outcome, timing, and study design framework, the evidence was assessed using Cochrane and PRISMA 2020 methodology. Eligible studies included prospective Phase II/II trials and select retrospective studies published between 5/1/2020 and 8/1/2025 in the Embase, Medline, and Pubmed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: ARS AUC recommendations include adjuvant FLOT chemotherapy for localized gastric adenocarcinoma after neoadjuvant FLOT and surgery, poCT or perioperative chemoimmunotherapy for localized gastric adenocarcinoma, adjuvant chemotherapy +/− CRT for localized gastric adenocarcinoma that undergoes upfront surgery, and systemic therapy alone for localized gastric adenocarcinoma in a medically inoperable patient. Conclusions: This updated ARS AUC summary provides guidelines for the multimodality treatment of resectable gastric adenocarcinoma.
Shape-sensing robotic-assisted bronchoscopy with integrated mobile cone-beam CT for small nodules: results from the prospective multicentre CONFIRM study
Husta, Bryan C, Cheng, George Z. , Batra, Hitesh , Reisenauer, J., Bartek, William, Kalchiem‐Dekel, Or , Zouk, Aline, Patel, Niral, Chawla, Mohit, Eapen, George A. , Jiménez, C. Delgado, Lee, R. J., Bott, Matthew J. , Oh, Scott , Casal, Roberto F, Casal, Roberto , Reisenauer, Janani , Zouk, Aline N., Patel, Niral M. , Chawla, Mohit , Casal, Roberto F.

Mayo Clinic

Thorax | February 16, 2026 | Volume: 81 | Issue: 3 | Pages: 267-275

10.1136/thorax-2025-223272 | PMID 41698810 Get It

Background The use of 3D imaging with navigation bronchoscopy has increased with the introduction of mobile cone-beam CT (mCBCT). Shape-sensing robotic-assisted bronchoscopy (ssRAB) integrated with mCBCT has been introduced to correct for CT to body divergence (CT-BD) during the biopsy of peripheral pulmonary nodules (PPNs). Methods Prospective observational multicentre study, enrolling patients with a PPN of ≤20 mm suspicious for malignancy, assessing tool-in-lesion (TIL), diagnostic yield, sensitivity for malignancy and incidence of pneumothorax or airway bleeding. Non-malignant index biopsies were followed for 12 months. Descriptive statistics are reported for all variables along with 95% CI for primary endpoints. Results 155 consecutive patients were enrolled at six centres. Median nodule size was 14.0 mm (IQR 11.0–17.0), with 54.8% of nodules (85/155) in the upper lobes, 25.8% (40/155) with CT bronchus sign present and median distance to the nearest pleural surface of 8.2 mm (IQR 1.8–20.0). TIL was achieved in 154/155 (99.4%, 95% CI 96.5 to 100.0) procedures. A median of two (IQR 1–3) mCBCT spins were performed, with median dose area product of 25.7 Gy · cm 2 (IQR 11.0–46.7). Diagnostic yield per the American Thoracic Society/American College of Chest Physicians (ATC/ACCP) definition was 89.0% (n=138/155; 95% CI 83.0 to 93.5) and sensitivity for malignancy was 91.5% (95% CI 86.4 to 96.5). No pneumothorax (0%, 95% CI 0.0 to 2.4) and two Nashville Grade three bleeding events were reported (1.3%, 95% CI 0.2 to 4.6). Interpretation The first prospective multicentre study of integrated ssRAB and mCBCT for small peripheral nodules resulted in diagnostic outcomes similar to those reported for transthoracic biopsy with a more favourable safety profile. Trial registration number ClinicalTrials.gov ID: NCT05562895 .
Editorial for “Evaluating Malignancy Detection in Small Renal Masses: Integrating the Pseudocapsule Into Clear Cell Likelihood Score”
Hibbert, Rebecca , Parvinian, Ahmad

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 5, 2026 | Volume: 63 | Issue: 6 | Pages: 1698-1699

10.1002/jmri.70258 | PMID 41640065 Get It

Role of Intermediate dose escalation of radiotherapy in the survival of unresectable stage III non-small cell lung cancer patients in the era of immunotherapy
Amin, Saber A., Lin, Chi, Ganti, A. Kishor, ZHEN, W, Zhang, Chi, Amin, Saber , Ganti, Apar Kishor , Zhen, Weining

Mayo Clinic

Frontiers in Oncology | January 28, 2026 | Volume: 15 | Issue: No issue available | Pages: No page available

10.3389/fonc.2025.1652522 | PMID 41685294 Get It

Background The role of dose escalation of radiotherapy (RT) in unresectable stage III NSCLC followed by immunotherapy is unclear. The objective of the current study is to investigate if intermediate dose escalation (IDE) is beneficial in stage III NSCLC patients who receive definitive concurrent chemoradiation (dcCRT) followed by immunotherapy. Materials and methods The study used data from the National Cancer database. Multivariable Cox regression analysis was used to assess the all-cause mortality of patients who received standard RT dose (SD) (60 Gy ± 10%) and IDE (64–74 Gy). Results 47,315 patients were diagnosed in the era before immunotherapy and received dcCRT only, while 4,947 patients were treated with dcCRT and immunotherapy. In the cohort with dcCRT only, patients who received SD had statistically significant worse mortality but clinically minimal difference compared to patients with IDE (HR: 1.09, 95% CI: 1.07-1.12; p<0.0001). In the era of immunotherapy, SD was still associated with worse mortality compared to IDE (HR: 1.17, 95% CI: 1.03-1.33; p=0.02). However, the survival benefit associated with IDE was only restricted to patients who started immunotherapy within six weeks after RT completion (HR: 1.26, 95% CI: 1.05-1.6; p=0.01). There was no difference in mortality between SD and IDE among patients who started immunotherapy between 7–10 weeks (HR: 1.13, 95% CI: 0.88-1.45; p=0.35) or >10 weeks after RT completion (HR: 0.74, 95% CI: 0.51-1.07; p=0.11). Conclusion IDE of RT is not needed for patients diagnosed with stage III unresectable NSCLC who receive immunotherapy > six weeks after dcCRT.
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR
Alger, Emily , Aiyegbusi, Olalekan Lee , Dueck, A. C. , Minchom, Anna, pe, madeline, Peipert, John Devin , Snyder, C. J., Symeonides, Stefan N. , Wilson, Roger , Basch, Ethan , Qiao, Yu , Dean, Lizzie, Hansen, Aaron R. , Kholmanskikh, Olga , Kobayashi, Ken, Tourneau, Christophe Le, Lee, J. Jack, Patel, Sheetal, Petrie, Joan, Pond, Gregory R. , Prior, Kieran, Rantell, Khadija , Reeve, John F., Solovyeva, O., Wages, Nolan A. , Weber, Harald A., Yap, C., Dueck, Amylou C. , Yap, Christina , Snyder, Claire , Minchom, Anna , Snyder, Claire , Bates, Susan E , Bulbeck, Helen , Di Maio, Massimo , Hansen, Aaron R , Kholmanskikh, Olga , Kobayashi, Ken , Landers, Dónal , Lee, J Jack , Ma, Brigette B Y , Marshall, Lynley V , Petrie, Joan , Pond, Gregory Russell , Solovyeva, Olga , Wages, Nolan A , Yap, Christina , Peipert, John Devin , Pe, Madeline , Basch, Ethan , Bates, Susan E. , Bulbeck, Helen , Tourneau, Christophe Le , Ma, Brigette , Weber, Harald, Calvert, Melanie

Mayo Clinic

Journal of Clinical Oncology | January 23, 2026 | Volume: 44 | Issue: 8 | Pages: 709-719

10.1200/jco-25-01625 | PMID 41576310 Get It

PURPOSE There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation—ultimately contributing to the development of safer, more effective therapies.
Suckerin Colloids and Hydrogels With Low Immunogenicity as Resorbable and Hemostatic Tissue Adhesives for Wound Healing
Lee, Suyoung , Yoo, Surim , Shebanova, Anastasia, Miserez, Ali , Hwang, Dong Soo , Deepankumar, Kanagavel , Shebanova, Anastasia , Miserez, Ali , Hwang, Dong Soo , Deepankumar, Kanagavel

Mayo Clinic

Small | January 21, 2026 | Volume: 22 | Issue: 16 | Pages: No page available

10.1002/smll.202512461 | PMID 41562884 Get It

ABSTRACT Squid sucker ring teeth proteins (suckerins) have recently been shown to exhibit higher molecular‐level adhesion than mussel adhesive proteins–a well‐known class of wet‐resistant adhesive proteins–and can also assemble into nanoparticles in aqueous conditions. Herein, we present recombinant suckerin‐12 colloids and hydrogels as bioadhesives with strong wet adhesion and excellent in vivo biocompatibility. These colloids and hydrogels displayed low cytotoxicity, minimal immunogenicity, and negligible hemolysis, while outperforming fibrin glue in hemostasis, skin cell proliferation and migration, wound closure, and healing. Suckerin hydrogels formulated via riboflavin‐mediated di‐tyrosine crosslinking preserved β‐sheet content and elasticity at an optimal crosslinking density, resulting in enhanced adhesion, hemocompatibility, and in vivo wound closure. Transcriptomic analysis further revealed regulation of genes associated with hemostasis, angiogenesis, proliferation, and re‐epithelialization, with minimal immune activation. Together, these findings establish suckerin‐based adhesives as promising next‐generation biomedical materials that combine scalability, stability under oxidative conditions, and superior performance for external wound repair.
Differential effects of small extracellular vesicles from head and neck cancer patients on dendritic cell functions
Huber, Diana , Yerneni, Sai Gopal Krishna, Hoffmann, Thomas K., Wollenberg, B., WHITESIDE, T, Hofmann, Linda , Ludwig, Sonja , Hoffmann, Thomas K., Wollenberg, Barbara , Theodoraki, Marie‐Nicole

Mayo Clinic

Frontiers in Oncology | January 14, 2026 | Volume: 15 | Issue: No issue available | Pages: No page available

10.3389/fonc.2025.1680167 | PMID 41613539 Get It

Background Tumor-derived small extracellular vesicles were shown to contribute to immunosuppression in various cancer types, including head and neck squamous cell carcinoma. Dendritic cells, major regulators of specific anti-tumor immune response, are often impaired in their function in the context of cancer. Methods Monocyte-derived dendritic cells were incubated with isolated small extracellular vesicles during or after maturation. Cell surface markers and antigen processing machinery were assessed by flow cytometry. Vesicle-treated dendritic cells were tested for interleukin 12p70 production by ELISA, and differences in uptake of labeled vesicles were shown by confocal microscopy. Results Small extracellular vesicles derived from HPV(+) tumor cell lines increased maturation and activation of immature dendritic cells, priming them for more rapid phagocytosis. Immature dendritic cells co-incubated with vesicles had lower levels of antigen presenting machinery components and produced less IL12p70 than controls, while similarly co-incubated mature dendritic cells remained unaffected. Vesicles in plasma of patients with head and neck cancer inhibited functions of mature dendritic cells by downregulating expression of antigen presenting machinery components. Conclusion Our results uncover mechanisms through which tumor-derived small extracellular vesicles modulate dendritic cell functions locally and systemically. These mechanisms may also affect dendritic cell-based vaccine efficacy.
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
Challagulla, Swetha, Pilon, Dominic , Meng, Yan, Xue, Mei, Chen, Zhuo, Wang, Yuxi, Yang, Keri, Xue, Mei , Ailawadhi, Sikander , Totev, Todor

Mayo Clinic

Expert Review of Hematology | January 13, 2026 | Volume: 19 | Issue: 3 | Pages: 321-331

10.1080/17474086.2026.2617270 | PMID 41528878 Get It